PE20120554A1 - Polipeptidos y metodo de tratamiento - Google Patents
Polipeptidos y metodo de tratamientoInfo
- Publication number
- PE20120554A1 PE20120554A1 PE2011002155A PE2011002155A PE20120554A1 PE 20120554 A1 PE20120554 A1 PE 20120554A1 PE 2011002155 A PE2011002155 A PE 2011002155A PE 2011002155 A PE2011002155 A PE 2011002155A PE 20120554 A1 PE20120554 A1 PE 20120554A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- seq
- refers
- amino acids
- variable domain
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000730032 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 5 Proteins 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000055053 human ADAMTS5 Human genes 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL O UN FRAGMENTO DEL MISMO QUE BLOQUEA LA ACTIVIDAD DE ADAMTS5 HUMANA QUE COMPRENDE SEIS CDR: i) CDRH1 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 2, ii) CDRH2 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 13, iii) CDRH3 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 18, iv) CDRL1 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 20, v) CDRL2 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 22, Y vi) CDRL3 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 27; EN DONDE EL DOMINIO VARIABLE DE CADENA PESADA VH COMPRENDE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE SEC ID Nº: 76, 80, 116, 118, 120, 122, 124, 126, 128, 136, 138, 140, 142 Y 144, Y EL DOMINIO VARIABLE DE CADENA LIGERA VL COMPRENDE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE SEC ID Nº: 78, 82, 130, 132, 134 Y 146. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ARTROSIS, ARTRITIS REUMATOIDE, ARTRITIS PSORIASICA, DEGENERACION DEL CARTILAGO, OSTEOPENIA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22252109P | 2009-07-02 | 2009-07-02 | |
| US24975709P | 2009-10-08 | 2009-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120554A1 true PE20120554A1 (es) | 2012-06-08 |
Family
ID=43411744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011002155A PE20120554A1 (es) | 2009-07-02 | 2010-07-01 | Polipeptidos y metodo de tratamiento |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120095193A1 (es) |
| EP (1) | EP2449127A4 (es) |
| JP (1) | JP2012531902A (es) |
| KR (1) | KR20120098587A (es) |
| CN (1) | CN102482700A (es) |
| AR (1) | AR077630A1 (es) |
| AU (1) | AU2010266272A1 (es) |
| BR (1) | BR112012000025A2 (es) |
| CA (1) | CA2766641A1 (es) |
| CL (1) | CL2011003354A1 (es) |
| CO (1) | CO6480976A2 (es) |
| CR (1) | CR20120027A (es) |
| DO (1) | DOP2011000404A (es) |
| IL (1) | IL217292A0 (es) |
| MA (1) | MA33387B1 (es) |
| MX (1) | MX2012000055A (es) |
| PE (1) | PE20120554A1 (es) |
| SG (1) | SG177288A1 (es) |
| TW (1) | TW201114436A (es) |
| UY (1) | UY32752A (es) |
| WO (1) | WO2011002968A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US20130336989A1 (en) * | 2011-02-24 | 2013-12-19 | Glaxo Group Limited | Methods of identifying a patient population |
| WO2013109829A1 (en) * | 2012-01-20 | 2013-07-25 | Glaxosmithkline Intellectual Property Development Ltd | Anti-adamts4 antibodies and methods of treatment |
| PL2650310T3 (pl) * | 2012-04-13 | 2017-01-31 | Rottapharm Biotech S.R.L. | Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania |
| WO2015056808A1 (en) * | 2013-10-15 | 2015-04-23 | Genefrontier Corporation | Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases |
| WO2017019729A1 (en) * | 2015-07-27 | 2017-02-02 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| CA3064469A1 (en) * | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Mmp13 binding immunoglobulins |
| AU2018277310B2 (en) * | 2017-06-02 | 2024-07-11 | Ablynx Nv | Aggrecan binding immunoglobulins |
| EP3630817A1 (en) * | 2017-06-02 | 2020-04-08 | Merck Patent GmbH | Polypeptides binding adamts5, mmp13 and aggrecan |
| KR20250011229A (ko) | 2017-06-02 | 2025-01-21 | 메르크 파텐트 게엠베하 | Adamts 결합성 면역글로불린 |
| CA3081823A1 (en) * | 2017-11-09 | 2019-05-16 | Ribomic Inc. | Aptamer for adamts5 and use for aptamer for adamts5 |
| CN110760483B (zh) * | 2019-11-08 | 2021-06-22 | 扬州大学 | 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用 |
| WO2021154534A1 (en) * | 2020-01-28 | 2021-08-05 | Promab Biotechnologies, Inc. | Plap-cd3 epsilon bispecific antibodies |
| WO2024054922A1 (en) * | 2022-09-07 | 2024-03-14 | Synoa Therapeutics, Llc | Methods and compositions comprising novel bispecific antibodies |
| CN119775410B (zh) * | 2025-03-11 | 2025-04-29 | 成都大熊猫繁育研究基地 | 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391610B1 (en) * | 1999-08-06 | 2002-05-21 | The Cleveland Clinic Foundation | Nucleic acids encoding zinc metalloproteases |
| WO2005061459A1 (en) * | 2003-12-04 | 2005-07-07 | Wyeth | Biaryl sulfonamides and methods for using same |
-
2010
- 2010-07-01 PE PE2011002155A patent/PE20120554A1/es not_active Application Discontinuation
- 2010-07-01 UY UY0001032752A patent/UY32752A/es unknown
- 2010-07-01 BR BR112012000025A patent/BR112012000025A2/pt not_active IP Right Cessation
- 2010-07-01 US US13/379,748 patent/US20120095193A1/en not_active Abandoned
- 2010-07-01 MA MA34497A patent/MA33387B1/fr unknown
- 2010-07-01 CA CA2766641A patent/CA2766641A1/en not_active Abandoned
- 2010-07-01 EP EP10794751A patent/EP2449127A4/en not_active Withdrawn
- 2010-07-01 AU AU2010266272A patent/AU2010266272A1/en not_active Abandoned
- 2010-07-01 CN CN2010800385288A patent/CN102482700A/zh active Pending
- 2010-07-01 SG SG2011094182A patent/SG177288A1/en unknown
- 2010-07-01 TW TW099121683A patent/TW201114436A/zh unknown
- 2010-07-01 MX MX2012000055A patent/MX2012000055A/es not_active Application Discontinuation
- 2010-07-01 KR KR1020127002804A patent/KR20120098587A/ko not_active Withdrawn
- 2010-07-01 JP JP2012517907A patent/JP2012531902A/ja not_active Withdrawn
- 2010-07-01 WO PCT/US2010/040724 patent/WO2011002968A2/en not_active Ceased
- 2010-07-01 AR ARP100102358A patent/AR077630A1/es not_active Application Discontinuation
-
2011
- 2011-12-26 DO DO2011000404A patent/DOP2011000404A/es unknown
- 2011-12-29 CL CL2011003354A patent/CL2011003354A1/es unknown
- 2011-12-29 IL IL217292A patent/IL217292A0/en unknown
- 2011-12-29 CO CO11181044A patent/CO6480976A2/es not_active Application Discontinuation
-
2012
- 2012-01-16 CR CR20120027A patent/CR20120027A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG177288A1 (en) | 2012-02-28 |
| JP2012531902A (ja) | 2012-12-13 |
| MA33387B1 (fr) | 2012-06-01 |
| CR20120027A (es) | 2012-05-16 |
| TW201114436A (en) | 2011-05-01 |
| KR20120098587A (ko) | 2012-09-05 |
| CL2011003354A1 (es) | 2012-07-20 |
| EP2449127A4 (en) | 2013-01-16 |
| CO6480976A2 (es) | 2012-07-16 |
| US20120095193A1 (en) | 2012-04-19 |
| AU2010266272A1 (en) | 2012-01-19 |
| DOP2011000404A (es) | 2012-04-15 |
| WO2011002968A3 (en) | 2011-04-07 |
| IL217292A0 (en) | 2012-02-29 |
| CN102482700A (zh) | 2012-05-30 |
| CA2766641A1 (en) | 2011-01-06 |
| UY32752A (es) | 2011-01-31 |
| MX2012000055A (es) | 2012-01-27 |
| WO2011002968A2 (en) | 2011-01-06 |
| EP2449127A2 (en) | 2012-05-09 |
| BR112012000025A2 (pt) | 2015-09-08 |
| AR077630A1 (es) | 2011-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| JP2020500538A5 (es) | ||
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| AR068723A1 (es) | Proteina que se une a antigenos que se une a il-23 humana y sus usos | |
| PE20120211A1 (es) | Anticuerpos que tienen especificidad por ox40 humana | |
| PE20091674A1 (es) | Antagonistas del receptor de glucagon | |
| PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
| FI3922645T3 (fi) | Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja | |
| NZ623347A (en) | Novel anti-dr5 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |